Lenzing's €300m Balancing Act: A Doubled Bottom Line Meets the Hard Math of Dilution
Published on 08/12/2026 at 05:51 | Redaktion boerse-global.de
The numbers Lenzing served up for the first half of 2026 tell two very different stories, depending on where you look. Revenue slipped from €1.34bn to €1.27bn year-on-year, while EBITDA softened to €239.2m from €268.6m, dragging the margin down from 20 percent to 18.9 percent. Yet net profit nearly doubled, jumping from €15.2m to €35.6m. The apparent contradiction is less a mystery than a signal: financing effects and one-off items are doing the heavy lifting below the operating line, even as the core business tightens its belt.
That belt-tightening is substantial. Management has confirmed plans to cut roughly 2,000 jobs worldwide by the end of 2027 — nearly a quarter of a workforce that stood at about 8,100 employees. The fibre production site in Heiligenkreuz is slated to wind down by the end of 2026, with the Grimsby facility in England following by the end of 2027; both are earmarked for sale. The broader strategy, dubbed "Grow Nonwovens, Reset Textiles," carries an annual savings target of up to €120m by the end of 2027, alongside further efficiency measures.
The market has taken a measured view of the transformation. Shares currently trade at €23.50, up a modest 1.08 percent since the start of the year and still 21.13 percent above the 52-week low of €19.40 hit in March. But the stock sits more than a fifth below its 52-week high of €29.75 and beneath all key moving averages — a technical picture that suggests investors are already pricing in considerable uncertainty.
That uncertainty crystallises on 25 August, when an extraordinary general meeting will vote on a rights-based capital increase of up to €300m. The raise is paired with new financing agreements of up to €300m, and existing liabilities have been extended to 2030, easing near-term refinancing pressure. Relative to a market capitalisation of roughly €907.5m, however, the potential dilution is anything but trivial. Shareholders who decline to exercise their rights face a significant shift in their ownership stakes.
The company has flagged up to €150m in potential impairment charges on property, plant and equipment for 2026, plus restructuring provisions of up to €40m that will weigh on EBITDA. The exact figures remain unfinalised, but the direction of travel is clear. Core shareholders — B&C Group, Suzano and Oberbank — have signalled their backing for the programme, which reduces the risk of the raise failing or being priced at unfavourable terms.
Restructuring of this scale brings more than financial strain — it also creates new workplace risks that need careful documentation. As operations are consolidated and sites wind down, keeping your risk assessments current becomes essential. A free toolkit with 41 ready-to-use templates and checklists helps you document hazards and protect your team through periods of change. Download the free Risk Assessment Toolkit
If the capital increase goes through and the financing arrangements proceed as planned, Lenzing gains breathing room well beyond the critical restructuring phase. The extended debt maturities remove the immediate pressure of refinancing, and a successful pivot toward nonwovens, combined with the expected cost savings from site closures, could see margins stabilise once the 2026 burden phase passes.
The bear case is equally straightforward. A €300m capital increase against a sub-€1bn market cap is a substantial ask, and the operational picture remains fragile — falling revenue paired with heavy one-off charges could weigh on full-year results even after the positive half-year surprise. Should shareholder approval falter, or the issue price come in well below current trading levels, the dilution pressure on existing investors would intensify sharply.
The next milestone after the August vote is the third-quarter report, expected on 5 November, which should offer the first concrete evidence of how the plant closures and cost measures are translating into operational performance. For now, the fate of Lenzing's turnaround rests on a single question: whether shareholders are willing to accept the dilution that funds the fix.
